| AGREE double-blind treatment period (Day 365) | ||||
|---|---|---|---|---|
| Efficacy parameter, n (%) | Patients with ≤6 mths disease duration at BL | Overall population (≤2 yrs disease duration at BL) | ||
| IV ABA+MTX | PBO+MTX | IV ABA+MTX | PBO+MTX | |
| n=167 | n=157 | n=256 | n=253 | |
| DAS28 remission | 73 (43.7) | 42 (26.8) | 106 (41.4) | 59 (23.3) |
| TS (X-ray), mean (SD) change from BL* | 0.46 (1.18) | 1.31 (2.93) | 0.63 (1.74) | 1.06 (2.45) |
| ACR 50 response | 100 (59.9) | 72 (45.9) | 147 (57.4) | 107 (42.3) |
| LDAS | 95 (56.9) | 63 (40.1) | 139 (54.3) | 93 (36.8) |
| HAQ-DI | 125 (74.9) | 103 (65.6) | 184 (71.9) | 157 (62.1) |
*≤6 mths: IV ABA+MTX, n=161; PBO+ MTX, n=149; Overall: IV ABA+MTX, n=218; PBO+ MTX, n=223.